CT Man with Early Alzheimer’s Finds Hope in Breakthrough Drug

BREAKING: A Connecticut man diagnosed with early onset Alzheimer’s has discovered promising treatment options that could change the course of his disease. Lee Ross, 61, learned of his diagnosis earlier this year after persistent memory issues prompted him to seek answers from medical professionals.

Ross, an attorney and father of two, recognized troubling signs when he struggled to find words and complete sentences. After rejecting suggestions of anxiety as a cause, he underwent extensive tests, ultimately confirming the diagnosis of Alzheimer’s disease. “I just knew that something wasn’t right,” he stated, highlighting the importance of self-advocacy in securing timely medical answers.

His diagnosis marks a critical juncture in his life, prompting an early retirement from his role as legislative director at the state judicial branch. “All of a sudden, I am an Alzheimer’s patient,” Ross remarked, reflecting on the emotional toll of sudden life changes. Despite the challenges, he has since learned about groundbreaking treatments available today.

Among these is Leqembi, a newly approved drug designed to slow the progression of Alzheimer’s by reducing amyloid plaque buildup in the brain. Developed by Eisai in collaboration with Biogen, Leqembi is aimed at individuals in the early stages of the disease. “I didn’t hesitate for a second,” Ross said about starting the treatment, emphasizing its potential to help maintain cognitive function.

However, treatment comes with risks, including headaches and potential brain swelling. Ross experienced some swelling but resumed the medication, stating, “The alternative is just not an option.”

Kristen Cusato, director of communications for the Alzheimer’s Association, noted that the advent of drugs like Leqembi represents a major shift in treatment options. “It creates a whole new world to treat patients,” she said, referencing the FDA’s approval of Leqembi and another drug, Kisunla. These advancements offer hope to the 80,000 people living with Alzheimer’s in Connecticut and their families.

On October 19, 2023, Ross will participate in the Walk to End Alzheimer’s at Rentschler Field. The event starts at 9 a.m., featuring a moving Promise Garden ceremony at 10 a.m. This initiative aims to raise awareness and funds for Alzheimer’s research, and Ross has rallied support from family and friends to join his team.

“I just felt, if I could do something, maybe my story would encourage others to get tested,” Ross said, emphasizing the critical nature of early diagnosis. His proactive approach not only led to his own treatment but also highlights the urgency of addressing Alzheimer’s disease before significant cognitive decline occurs.

Research indicates that amyloid plaque can accumulate up to 20 years before symptoms manifest, making early intervention vital. The Alzheimer’s Association encourages individuals to recognize early signs such as memory changes, difficulty completing familiar tasks, and confusion about time or place. “Take charge of your own brain health,” Cusato urged, advocating for proactive healthcare engagement.

For anyone seeking more information about Alzheimer’s or related support, the Alzheimer’s Association offers a 24/7 Helpline at 1-800-272-3900 and resources at alz.org/ct.

As Ross navigates his journey with Alzheimer’s, he remains optimistic about the future. “I hope to stay this way for quite a while,” he concluded, embodying the strength and resilience that many families living with Alzheimer’s strive to maintain.